NuVasive Inc expanded its partnership with the International Spine Study Group Foundation (ISSGF) with the launch of two new clinical studies. These studies …
Jefferies analyst Raj Denhoy reiterates his Buy rating on NuVasive, Inc. (NASDAQ:NUVA) with a price target of $72.
